A Randomized Discontinuation Phase 2 Study of AZD0530 as a Metastasis Inhibitor in Castrate Resistant Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2013
At a glance
- Drugs Saracatinib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 01 Aug 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Aug 2012 Planned End Date changed from 1 Feb 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 20 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.